ACHV vs. RIGL, EBS, XOMA, LXRX, VNDA, CDXS, SGMO, IRWD, DOMH, and AGEN
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include Rigel Pharmaceuticals (RIGL), Emergent BioSolutions (EBS), XOMA (XOMA), Lexicon Pharmaceuticals (LXRX), Vanda Pharmaceuticals (VNDA), Codexis (CDXS), Sangamo Therapeutics (SGMO), Ironwood Pharmaceuticals (IRWD), Dominari (DOMH), and Agenus (AGEN). These companies are all part of the "biotechnology" industry.
Achieve Life Sciences vs.
Achieve Life Sciences (NASDAQ:ACHV) and Rigel Pharmaceuticals (NASDAQ:RIGL) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability, community ranking and analyst recommendations.
Rigel Pharmaceuticals received 133 more outperform votes than Achieve Life Sciences when rated by MarketBeat users. However, 70.46% of users gave Achieve Life Sciences an outperform vote while only 68.88% of users gave Rigel Pharmaceuticals an outperform vote.
In the previous week, Achieve Life Sciences had 10 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 14 mentions for Achieve Life Sciences and 4 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 1.54 beat Achieve Life Sciences' score of 0.63 indicating that Rigel Pharmaceuticals is being referred to more favorably in the news media.
Rigel Pharmaceuticals has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 66.2% of Rigel Pharmaceuticals shares are held by institutional investors. 2.0% of Achieve Life Sciences shares are held by company insiders. Comparatively, 9.5% of Rigel Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Achieve Life Sciences presently has a consensus target price of $14.33, suggesting a potential upside of 339.67%. Rigel Pharmaceuticals has a consensus target price of $36.40, suggesting a potential upside of 80.91%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Achieve Life Sciences is more favorable than Rigel Pharmaceuticals.
Rigel Pharmaceuticals has a net margin of 2.46% compared to Achieve Life Sciences' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of -14.80% beat Achieve Life Sciences' return on equity.
Achieve Life Sciences has a beta of 1.49, indicating that its stock price is 49% more volatile than the S&P 500. Comparatively, Rigel Pharmaceuticals has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500.
Summary
Rigel Pharmaceuticals beats Achieve Life Sciences on 11 of the 17 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ACHV) was last updated on 5/21/2025 by MarketBeat.com Staff
